Effects of Carnitine on Oxidative Stress to IVIR Administration to CKD Patients:Impact of Haptoglobin Genotype
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Anemia is a common disorder in CKD patients. It is largely attributed to decreased
erythropoietin (EPO) production and iron deficiency. Therefore, besides EPO, therapy includes
iron replenishment. However, the latter induces oxidative stress. Haptoglobin (Hp) protein is
the main line of defense against the oxidative effects of Hemoglobin/Iron. There are 3
genotypes: 1-1, 2-1 and 2-2. Hp 2-2 protein is inferior to Hp 1-1 as antioxidant. So far,
there is no evidence whether haptoglobin genotype affects iron-induced oxidative stress in
CKD patients.
In this proposed study we wished to examine whether Hp genotype influences intravenous iron
administration (IVIR)-induced oxidative stress in CKD patients, and its impact on the
response of these patients to L-Carnitine therapy.